We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Diagnosed Anemia Linked to Crohn’s Disease Risk

By LabMedica International staff writers
Posted on 28 Sep 2020
Print article
Image: Comparison of histology between ulcerative colitis and Crohn’s disease (Photo courtesy of R. J. Xavier & D. K. Podolsky).
Image: Comparison of histology between ulcerative colitis and Crohn’s disease (Photo courtesy of R. J. Xavier & D. K. Podolsky).
Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC). IBD is a chronic inflammatory gastrointestinal disorder that involves complex interactions among genetic, environmental, immunological, and microbiological factors.

Anemia can be caused by a variety of etiologies such as iron deficiency, chronic diseases, vitamin B12 or folate deficiency, and genetic factors. Anemia is a known risk factor for cardiovascular diseases, dementia, and chronic medical illness, leading to an increase in all-cause mortality.

Medical scientists from the Seoul National University College of Medicine (Seoul, South Korea) conducted a population-based study from a database for patients during 2009, during which time 9,962,064 individuals older than 20 years, who participated in the national health screening program. Anemia was defined as a hemoglobin level less than 13 g/dL in men and less than 12 g/dL in women. The investigators compared the rate of newly diagnosed IBD in anemic and non-anemic patients.

The team reported that during the mean follow-up period of 7.3 years, the incidences of CD and UC in anemic patients were 2.89 and 6.88 per 100,000 person-years, respectively. The risk of CD was significantly higher in anemic patients than in non-anemic individuals [adjusted hazard ratio (aHR), 2.084; 95% confidence interval (CI), 1.769–2.455]. The risk of CD development was inversely proportional to the hemoglobin concentration. A J-curve relationship was observed between age and the risk of CD in anemic patients. The risk of CD in male anemic patients was significantly higher than that in female anemic patients (aHR, 1.432 versus 1.240, respectively). By contrast, there was no statistically significant difference in the risk of developing UC in anemic and non-anemic individuals (aHR, 0.972; 95% CI, 0.880–1.073).

The risk of CD development was correlated with the severity of anemia as determined by the hemoglobin level. When patients were stratified with respect to hemoglobin levels, the risk of CD was 3.3 times higher in the lowest 10% group than in the highest 10% group. Jong Pil Im, MD, PhD, a professor of Internal Medicine and a senior author of the study, said, “To the best of our knowledge, this is the first epidemiological study to demonstrate the association between anemia and the development of inflammatory bowel disease in the general population.”

The authors concluded that patients with anemia, especially newly developed anemia, were associated with an increased risk of developing CD, not UC. The risk of developing CD was inversely proportional to the hemoglobin level, which was a marker for anemia severity. A J-curve relationship was observed between age and the risk of developing CD among anemic patients, similar to that observed for the incidence of CD based on age. The study was published on September 8, 2020 in the journal PLOS ONE.

Related Links:
Seoul National University College of Medicine

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.